Prestige Consumer Healthcare Inc. $PBH Stock Holdings Increased by Citigroup Inc.

Key Points

• Citigroup Inc. increased its stake in Prestige Consumer Healthcare by 21.6% to own 105,428 shares, which are valued at approximately $9.06 million.
• Prestige Consumer Healthcare reported a 6.6% decrease in quarterly revenue year-over-year, missing analyst expectations with earnings of $0.95 per share compared to a consensus of $1.01.
• Currently, the stock has an average rating of “Hold” from analysts, with a consensus target price of $93.33.

Citigroup Inc. raised its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 21.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 105,428 shares of the company's stock after acquiring an additional 18,759 shares during the quarter. Citigroup Inc. owned 0.21% of Prestige Consumer Healthcare worth $9,064,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Neumeier Poma Investment Counsel LLC acquired a new stake in Prestige Consumer Healthcare in the 1st quarter valued at about $8,713,000. Charles Schwab Investment Management Inc. lifted its holdings in Prestige Consumer Healthcare by 1.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 642,390 shares of the company's stock valued at $55,226,000 after acquiring an additional 6,370 shares during the last quarter. Westwood Holdings Group Inc. lifted its holdings in Prestige Consumer Healthcare by 7.1% in the 1st quarter. Westwood Holdings Group Inc. now owns 861,282 shares of the company's stock valued at $74,044,000 after acquiring an additional 56,802 shares during the last quarter. Costello Asset Management INC purchased a new stake in Prestige Consumer Healthcare during the first quarter valued at about $112,000. Finally, Blair William & Co. IL lifted its stake in Prestige Consumer Healthcare by 16.4% during the first quarter. Blair William & Co. IL now owns 106,114 shares of the company's stock valued at $9,123,000 after buying an additional 14,967 shares in the last quarter. 99.95% of the stock is owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Trading Up 0.7%

PBH stock traded up $0.4350 during mid-day trading on Thursday, reaching $65.4850. 546,401 shares of the stock traded hands, compared to its average volume of 569,653. The stock's fifty day moving average is $75.63 and its 200-day moving average is $81.25. The company has a current ratio of 4.38, a quick ratio of 2.99 and a debt-to-equity ratio of 0.55. The company has a market cap of $3.22 billion, a P/E ratio of 15.37, a P/E/G ratio of 2.05 and a beta of 0.43. Prestige Consumer Healthcare Inc. has a 52-week low of $62.95 and a 52-week high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.95 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.01 by ($0.06). The company had revenue of $249.53 million during the quarter, compared to analysts' expectations of $260.71 million. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.Prestige Consumer Healthcare's revenue for the quarter was down 6.6% compared to the same quarter last year. During the same period last year, the company earned $0.90 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. As a group, sell-side analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Analyst Ratings Changes

PBH has been the subject of a number of analyst reports. Wall Street Zen lowered shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Canaccord Genuity Group reduced their price objective on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Finally, Royal Bank Of Canada raised shares of Prestige Consumer Healthcare to a "hold" rating in a research note on Thursday, May 8th. Three investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $93.33.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.